Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + sofosbuvir + daclatasvir
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of hydroxychloroquine, sofosbuvir, and daclatasvir that was investigated for the treatment of moderate to severe COVID-19. Sofosbuvir is a nucleotide inhibitor of the viral RNA polymerase NS5B, daclatasvir is a viral NS5A inhibitor, and hydroxychloroquine was initially used as part of standard care for COVID-19 early in the pandemic. Clinical trials showed that adding sofosbuvir and daclatasvir to standard care (which included hydroxychloroquine) significantly reduced the duration of hospital stay compared to standard care alone.
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on hydroxychloroquine + sofosbuvir + daclatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + sofosbuvir + daclatasvir.